Larimar Therapeutics Inc (LRMR)

05:52 AM

What drives Larimar Therapeutics Inc. stock priceFree Technical Analysis Support - Autocar Professional

05:52 AM

03:59 AM

What analysts say about Larimar Therapeutics Inc. stockConsistent wealth multiplication - PrintWeekIndia

03:59 AM

Jul 19, 2025

Larimar Therapeutics Inc. Stock Analysis and ForecastRobust investment performance - Jammu Links News

Jul 19, 2025

Jul 19, 2025

Is Larimar Therapeutics Inc. a good long term investmentSuperior stock selection - Jammu Links News

Jul 19, 2025

Jul 18, 2025

Is Larimar Therapeutics Inc. stock overhyped or has real potentialHigh Potential Shares - Newser

Jul 18, 2025

Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance

Jul 17, 2025

Jul 15, 2025

What makes Larimar Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025

Jul 15, 2025

Why Larimar Therapeutics Inc. stock attracts strong analyst attentionAI Powered Stock Call - Newser

Jul 15, 2025

Jul 12, 2025

Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN

Jul 12, 2025

Jul 09, 2025

Larimar Nears Data Readout For Nomlabofusp In Rare Inherited Disorder - RTTNews

Jul 09, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - MarketScreener

Jul 08, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia | LRMR Stock News - GuruFocus

Jul 08, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment - Nasdaq

Jul 08, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting - GlobeNewswire

Jul 08, 2025

Jul 08, 2025

First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan

Jul 08, 2025

Jun 30, 2025

Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000 Value Index - MarketScreener

Jun 30, 2025

Jun 26, 2025

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN

Jun 26, 2025

Jun 25, 2025

Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN

Jun 25, 2025

Jun 25, 2025

Larimar Therapeutics’ (LRMR) Buy Rating Reaffirmed at Guggenheim - Defense World

Jun 25, 2025

Jun 24, 2025

Guggenheim Reiterates Buy Rating on Larimar Therapeutics (LRMR) - GuruFocus

Jun 24, 2025

Jun 24, 2025

Larimar Therapeutics (LRMR) Sees Buying Opportunity After Share Decline | LRMR Stock News - GuruFocus

Jun 24, 2025

Jun 24, 2025

Analyst Lowers Price Target for Larimar Therapeutics (LRMR) | LR - GuruFocus

Jun 24, 2025

Jun 23, 2025

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program | LRMR Stock News - GuruFocus

Jun 23, 2025

Jun 21, 2025

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - The Manila Times

Jun 21, 2025

Jun 20, 2025

Crucial FDA Update Coming: Larimar's Breakthrough Friedreich's Ataxia Drug Faces Regulatory Milestone - Stock Titan

Jun 20, 2025

Jun 17, 2025

Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus

Jun 17, 2025

Jun 10, 2025

Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 10, 2025

Jun 04, 2025

ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 04, 2025

May 28, 2025

Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

May 28, 2025

May 23, 2025

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN

May 23, 2025

May 23, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa

May 23, 2025

May 22, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com

May 22, 2025

May 18, 2025

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo

May 18, 2025

May 13, 2025

Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

May 13, 2025

May 08, 2025

Why Did Larimar Therapeutics Soar 10.14% on Q1 Earnings? - AInvest

May 08, 2025

May 05, 2025

LRMRLarimar Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

May 05, 2025

May 04, 2025

Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks

May 04, 2025

May 02, 2025

Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel

May 02, 2025